MetaVia Inc. presented preclinical data at ObesityWeek 2026 showing its dual-agonist DA-1726 achieved weight loss comparable to retatrutide in mice, with 41.7% reduction at high doses. The study highlighted superior glucose lowering and increased hepatic FGF21 expression, supporting the company's focus on liver-related cardiometabolic diseases. MetaVia plans to initiate a Phase 2 study for MetALD and ALD in the second half of 2027.
Head-to-head preclinical data presented on November 14, 2026 at ObesityWeek 2026 showed DA-1726 matched retatrutide's weight loss (41.7% vs 43.6% high dose) with greater glucose lowering (43.0% vs 32.5%) and significantly increased hepatic FGF21 (p<0.001), supporting the liver-disease focus. For a clinical-stage biotech this is a supportive datapoint, but it is mouse data and the Phase 2 study in MetALD and ALD is not targeted until the second half of 2027, which limits the near-term re-rating.
- ▲ Positive head-to-head preclinical data vs retatrutide presented November 14, 2026 at ObesityWeek 2026
- ▲ Phase 2, 48-week study of DA-1726 in MetALD and ALD planned to begin in the second half of 2027
- ▼ All new data are preclinical, from diet-induced obese mice over roughly three weeks, not from humans
- ▼ Confirmatory efficacy is only planned for a Phase 2 study starting in the second half of 2027